Objectives. The recent expansion of eligibility for cochlear implantation (CI) by the U.S. Food and Drug Administration (FDA) to include infants as young as 9 months has reignited debates concerning the clinically appropriate cut-off age for pediatric CI. Our study compared the early postoperative trajectories of receptive and expressive language development in children who received CI before 9 months of age with those who received it between 9 and 12 months. This study involved a unique pediatric cohort with documented etiology, where the timing of CI was based on objective criteria and efforts were made to minimize the influence of parental socioeconomic status.Methods. A retrospective review of 98 pediatric implantees recruited at a tertiary referral center was conducted. The timing of CI was based on auditory and language criteria focused on the extent of delay corresponding to the bottom 1st percentile of language development among age-matched controls, with patients categorized into very early (CI at <9 months), early (CI at 9–12 months) and delayed (CI at 12–18 months) CI groups. Postoperative receptive/expressive language development was assessed using the Sequenced Language Scale for Infants receptive and expressive standardized scores and percentiles.Results. Only the very early CI group showed significant improvements in receptive language starting at 3 months post-CI, aligning with normal-hearing peers by 9 months and maintaining this level until age 2 years. During this period (9 months), in children with profound deafness who have a clear deafness etiology and language development delays (<1st percentile).
10 January 2020 in Journal of Audiology and Otology
Background and Objectives: Systemic steroid therapy (SST) and intratympanic steroid injection (ISI) have been the treatment of choice for sudden sensorineural hearing loss (SSNHL). We studied the effect of ISI administered at different intervals on hearing outcomes in patients with SSNHL. Subjects and Methods: We performed a retrospective study of 427 patients diagnosed with SSNHL at Bundang Jesaeng Hospital, of whom 51 patients with SSNHL who received SST and four ISIs were included in this study. Patients were treated with four ISIs either every day for 4 days (group 1) or at intervals (mean duration of interval: 2.21 days) (group 2). Hearing outcomes were evaluated using the pure-tone test before the injection and 14 days, 1 month, and 3 months after the final injection. Recovery rates were classified based on Siegel's criteria. Results: The amount of improvement was 27.67 dB (+/- 20.45) in group 1 and 32.79 dB (+/- 21.42) in group 2. However, there were no significant differences between the two groups (p= 0.714). The recovery rates based on Siegel's criteria were 18/27 (66.7%) and 16/24 (66.7%) in groups 1 and 2, respectively, with no significant difference (p=1.000). Considering only complete recoveries in hearing recovery, the recovery rates were 15/27 (55.6%) and 14/24 (58.3%) in groups 1 and 2, respectively, with no significant difference (p=0.842). Conclusions: There were no significant differences in hearing outcomes or recovery rates after ISI administration every day or at intervals of 2-3 days.
31 December 2023 in Journal of Clinical Otolaryngology
Solitary fibrous tumor (SFT) is a rare benign spindle-cell neoplasm, most often found in the pleura. Recently, it has been reported to appear throughout the body but rarely in head and neck region. Tumors in the external auditory canal, in particular, have been very rarely reported. We experienced a case of a 55-year-old male with a 6-month history of progressive swelling from the orifice of left external auditory canal. The tumor was round, well circumscribed, almost completely obstructing the left external auditory canal. On the enhanced temporal bone CT and enhanced paranasal sinus MRI, a 2.0×1.7 cm sized mass was observed at the left external auditory canal. He was treated with surgical excision under general anesthesia. Histopathologic examination confirmed the diagnosis of SFT. This case report presents a rare case of a SFT arising in the external auditory canal.
21 December 2022 in Korean Journal of Otorhinolaryngology-Head and Neck Surgery
High-grade B cell lymphoma not otherwise specified (HGBL, NOS) is a new diagnostic category of non-Hodgkin lymphoma (NHL) based on World Health Organization statement in 2016. Up to 40% of NHLs are located in the extra-nodal area, commonly involving the gastrointestinal tract, head and neck region, bone and skin. The diagnosis of NHL originating from the inferior turbinate (IT) is rare, and there have been no reported cases yet of HGBL, NOS in IT. In this study, we report on a 43-year-old female who had a nasal polyp in IT and was diagnosed with HGBL, NOS after surgery. Endoscopic polypectomy under general anesthesia was performed. A histopathological report confirmed the resected specimen as HGBL, NOS, with a clear resection margin. Nasal obstruction was improved immediately after surgery and the patient was followed up for 10 months without any recurrence or complications.
21 December 2022 in Korean Journal of Otorhinolaryngology-Head and Neck Surgery
It is rare to find tumor of the ceruminous gland, which is a modified apocrine gland located within the skin of external auditory canal (EAC). Syringocystadenoma papilliferum (SCAP) is a benign adnexal tumor that occurs in the head and facial area in forms of infiltrative macules, papules, or keratinous nodules, but rarely in the EAC. To date, fewer than 150 case reports of SCAP have been reported, with SCAP in the EAC being extremely rare. We report a case of 51-year-old male with 2 year-history of a left EAC mass arising from the superior wall of the EAC. We performed a microscopic surgery, with the mass resected via retro-auricular approach under general anesthesia. The histopathological examination confirmed the specimen as SCAP. There were no complications or recurrence during the 4 months follow-up period.